Quick Facts
About OFEV

Home Why Choose OFEV? Quick Facts About OFEV

Your idiopathic pulmonary fibrosis (IPF) isn’t contagious, but your determination in the battle with IPF is. Keep fighting to inspire your loved ones by taking OFEV® (nintedanib).

OFEV is the only twice-daily pill for IPF that helps slow progression in 2 ways—by reducing the rate of lung function decline and reducing the risk of an acute exacerbation. Read below to learn more quick facts about OFEV.

QUICK
FACTS

OFEV is a Prescription Medicine for IPF

Not shown at actual size.

FACT 1: OFEV Is a Prescription Medicine for IPF

OFEV is a prescription medicine for IPF that is known to block some of the activity in the cells that causes scarring of the lungs.

Not shown at actual size.

OFEV is a Pill Taken Twice Daily

FACT 2: OFEV Is a Pill Taken Twice-Daily

The recommended dose of OFEV is 1 pill, twice a day with food. One in the morning and 1 in the evening, about 12 hours apart from each other.

OFEV May Help Reduce the Rate of Lung Function Decline

FACT 3: OFEV May Help Reduce the Rate of Lung Function Decline

Clinical studies have shown that OFEV reduced the rate of lung function decline compared to those who were not treated.

see how ofev slowed the progression of ipf
OFEV May Help Reduce the Risk of Acute Exacerbation

FACT 4: OFEV May Help Reduce the Risk of an Acute Exacerbation

OFEV may also reduce the risk of having an acute exacerbation.

WATCH HOW
OFEV CAN HELP

Watch this video to see how OFEV helps slow IPF progression.

If you'd like to skip to a different chapter, simply tap on the   icon below.

  • IPF is a serious and progressive lung disease that may impact both lungs and worsens over time, causing irreversible and permanent damage. Healthy lungs work by expanding to take in oxygen, which then travels through your bloodstream to your entire body.

  • IPF affects the lungs, causing them to lose the ability to expand fully and therefore take in less oxygen, which causes shortness of breath. Everyone experiences decline in lung function as they age, but patients with IPF lose lung function at a rate of 3 to 4 times more.

  • Some patients experience a severe and sudden worsening of their symptoms called an acute exacerbation. These events can leave patients with less lung function and is a possible sign that IPF is getting worse.

  • OFEV is an FDA-approved medicine that helps slow lung function decline in patients with IPF. In 3 out of 3 medical studies, taking OFEV slowed the decline in lung function by approximately 50%. In 2 out of 3 medical studies, OFEV significantly reduced the risk of a first acute exacerbation.

Jeanne, OFEV Mentor, Diagnosed with IPF in 2016

“I felt such relief knowing I had treatment options, such as OFEV.”

Jeanne, OFEV Mentor, Diagnosed with IPF in 2016

“I felt such relief knowing I had treatment options, such as OFEV.”Jeanne, OFEV Mentor, Diagnosed with IPF in 2016
 
Jeanne, OFEV Mentor, Diagnosed with IPF in 2016